（1） 肝病病程中核受体动态调控规律与失衡机制研究。
（2） 代谢相关脂肪性肝病及肝纤维化的治疗药物及策略研究。

(1) 国家自然科学基金委员会，青年科学基金项目（C类）[原青年科学基金项目]，82204512，肝损伤状态下FXR激动剂脱靶产生肝毒性的分子靶标和机制研究，2023-01-01至2025-12-31，30万元，在研，主持。
(2) 江苏省卓越博士后计划，2022ZB312，肝损伤状态下FXR激动剂脱靶产生肝毒性的分子靶标和机制研究，2021-07-01至2024-06-30，30万元，结题，主持。
(3) 国家自然科学基金委员会，重点项目，81930109，非酒精性脂肪肝进程中DAMPs代谢免疫调控与靶标发现，2020-01-01至2024-12-31，298万元，资助期满，参与。

(1) Wanfeng Xu#, Yun Wang#, Shuang Cui#, Qiuling Zheng, Yanghao Lin, Qingqing Cui, Yuxin Xie, Yuming Zeng, Chuan Zhang, Yujie Li, Xin Jin, Minna Qin, Huiyong Sun, Haiping Hao*, Lijuan Cao*; Methylcobalamin protects against liver failure via engaging gasdermin E, Nature Communications, 2025, 16(1): 1233. (IF: 16.6)
(2) Shuang Cui, Huijian Hu, An Chen, Ming Cui, Xiaojie Pan, Pengfei Zhang, Guangji Wang, Hong Wang*, Haiping Hao*; SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR, Acta Pharmaceutica Sinica B, 2023, 13(2): 559-576. (IF: 14.7)
(3) Shuang Cui#, Xiaojie Pan#, Chaoliang Ge, Yitong Guo, Pengfei Zhang, Tingting Yan, Jiyu Zhou, Qingxian He, Longhao Cheng, Guangji Wang*, Haiping Hao*, Hong Wang*; Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor a, Chinese Journal of Natural Medicines, 2021, 19(6): 401-411. (IF: 4.0)
(4) Jiyu Zhou, Shuang Cui, Qingxian He, Yitong Guo, Xiaojie Pan, Pengfei Zhang, Ningning Huang, Chaoliang Ge, Guangji Wang*, Frank J. Gonzalez*, Hong Wang*, Haiping Hao*; SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis, Nature Communications, 2020, 11(1): 240. (IF: 16.6)